-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
To date, despite multiple trials of neuroprotective treatments, none have been definitively shown to alter Parkinson's disease (PD) progression
Evidence suggests that it may have higher sensitivity to detect changes than gait changes assessed by UPDRS III
Abnormalities detected on semiquantitative exercise testing were earlier and more intense in patients with isolated rapid eye movement sleep behavior disorder (iRBD) than those detected in UPDRS/MDS-UPDRS III exercise testing (HR: 3.
The article was published in the Journal of Neurology, Neurosurgery & Psychiatry .
The longitudinal cohort study involved (1) iRBD patients (confirmed by polysomnography according to the International Classification of Sleep Disorders 3rd edition criteria), (2) idiopathic Parkinson's disease (3) age-matched and sex-matched controls
A total of 1497 participants provided the complete dataset at one or more visits (visits: control 362; iRBD 591; PD 2898; median years of follow-up: iRBD: 1.
statistics
Histograms showing the distribution of (A) composite clinical motor scores and (B) MDS-UPDRS III scores by disease group
Principal component analysis (PCA)32 was used to analyze the complete datasets (MDS-UPDRS III, Purdue pegboard trial total data and TUG) from controls and individuals with iRBD and PD, and the MATLAB function PCA was used to convert 18 The data of different visits in the month are regarded as independent data
Principal component analysis (PCA)32 was used to analyze the complete datasets (MDS-UPDRS III, Purdue pegboard trial total data and TUG) from controls and individuals with iRBD and PD, and the MATLAB function PCA was used to convert 18 The data of different visits in the month are regarded as independent data
Scatter plot of the relationship between composite clinical motor scores
Forty-six control group participants returned for a second in-person assessment and provided data to calculate a composite clinical motor score
There was a high correlation coefficient (absolute r=0.
LoC ,AroraS ,LawtonM , et alA composite clinical motor score as a comprehensive and sensitive outcome measure for Parkinson's disease LoC, Arora S, Lawton MLo CLoArora SAroraLawton MLawton, et alA composite clinical motor score as a comprehensive and sensitive outcome measure for Parkinson's diseaseJournal of Neurology, Neurosurgery & Psychiatry Published Online First: 06 April 2022.
doi: 10.
1136/jnnp-2021-327880 Journal of Neurology, Neurosurgery & Psychiatry Published Online First: 06 April 2022.
Published Online First: doi: 10.
1136/jnnp-2021-327880 doi:
Leave a message here
